Lung Cancer News & Features

New PCR-Based Assay Better Predicts Lung Cancer Survival

January 27, 2012

Assay identifies which early-stage NSCLC patients are at high risk of death after surgical resection
 

Bevacizumab delays return of ovarian cancer

Delicia Honen Yard January 13, 2012

The use of bevacizumab (Avastin) improved progression-free survival in women with ovarian cancer, particularly those at high risk for disease progression.
 

ACS annual report says cancer mortality is decreasing

Delicia Honen Yard January 10, 2012

Cancer incidence rates in men declined by 0.6% per year and remained stable in women and cancer mortality fell by 1.8% per year for men and by 1.6% per year for women between 2004 and 2008.
 

Cancer-Related Mortality Continues to Decrease

January 04, 2012

Overall cancer rates have decreased for men and remained stable for women, but mortality from cancer has declined for both sexes, according to a report from the American Cancer Society.
 

High EGFR plus cetuximab extends survival in lung cancer

Delicia Honen Yard November 23, 2011

People with advanced non-small cell lung cancer tumors expressing high levels of epidermal growth factor receptor are more likely to benefit when cetuximab (Erbitux) is used with chemotherapy.
 

Cancer risk doubles for organ-transplant recipients

Delicia Honen Yard November 21, 2011

Compared with the general population, recipients of a kidney, liver, heart, or lung transplant have twice as great a risk for diverse infection-related and unrelated cancers.
 

Vaccine may enhance NSCLC treatment

Delicia Honen Yard November 09, 2011

Recent study results suggest that a targeted immunotherapy based on a poxvirus may make chemotherapy for advanced non-small cell lung cancer more effective and slow disease progression.
 

No survival benefit to high-dose radiation in stage III lung cancer

Delicia Honen Yard October 27, 2011

Researchers have determined that the standard radiation dose of 60 Gy should remain in place for persons with stage III non-small cell lung cancer (NSCLC).
 

Costly clots common in cancer

Delicia Honen Yard October 18, 2011

As many as 1 in 5 people risk developing a venous thromboembolism (VTE) within a year after undergoing treatment for some types of cancers, researchers reported.
 

Bevacizumab label now warns of ovarian, osteonecrosis risks

Delicia Honen Yard October 12, 2011

The FDA has announced labeling changes for bevacizumab (Avastin), indicated for the treatment of glioblastoma and colorectal, breast, kidney, and nonsquamous non-small cell lung cancers.
 

Lung Cancer Clinical Trials

Clinical Trial: Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Clinical Trial: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Clinical Trial: Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot be Removed by Surgery or Transplant

Clinical Trial: Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis

Clinical Trial: Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery

Free CE from mycme.com

Discussions on Emerging Concepts and Controversies in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

2.00 / AMA PRA Category 1 Credit(s)TM
This program reviews developments in maintenance therapy and evaluates the relevance of tumor histology and biomarker analysis for the management of NSCLC patients.
 

Cancer care is expensive.
CancerCare can help.


Connect Booklets
Visit Reflections for first-hand stories on the power of the patient to impact caregivers in oncology nursing.
 Subscribe to the RSS for this page  [view all our RSS feeds here]

Web Exclusives

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions